HVTN 078
Status:Completed
Phase:I
Principal Investigator(s):Giuseppe Pantaleo, CTU Lausanne
Objective:To examine the safety of and immune responses to two vaccines expressing synthetic HIV proteins: NYVAC-B (a poxvirus), and rAd5 (an adenovirus).last updated March 27, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionThirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionFifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionFifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionFifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT00961883
Trial Sponsors:
EuroVacc Foundation, HVTN, NIAID
Start Date
End Date
August 31, 2009
January 31, 2013
Enrollment:80
Age range:
18 Years ↔
45 Years
Population:Cisgender Men, Cisgender Women